Valuation: Royalty Pharma plc

Market Cap 27.72B 24.7B 22.87B 20.69B 38.99B 2,616B 39.45B 274B 108B 1,375B 104B 102B 4,381B P/E 2026 *
25.3x
P/E 2027 * 17.9x
Enterprise Value 36.71B 32.71B 30.29B 27.41B 51.64B 3,464B 52.25B 363B 142B 1,821B 138B 135B 5,803B EV / Sales 2026 *
10.5x
EV / Sales 2027 * 9.64x
Free-Float
72.42%
Yield 2026 *
1.62%
Yield 2027 * 1.74%
1 day+0.10%
1 week+5.64%
Current month+6.78%
1 month+6.63%
3 months+6.67%
6 months+25.94%
Current year+61.27%
1 week 59.5
Extreme 59.5
62.9
1 month 55.13
Extreme 55.13
62.9
Current year 38.29
Extreme 38.29
64.38
1 year 35.92
Extreme 35.915
64.38
3 years 24.05
Extreme 24.05
64.38
5 years 24.05
Extreme 24.05
64.38
10 years 24.05
Extreme 24.05
64.38
Manager TitleAgeSince
Chief Executive Officer 62 31/12/1995
Director of Finance/CFO 44 31/12/2009
Chief Tech/Sci/R&D Officer - 20/09/2023
Director TitleAgeSince
Chairman 62 31/03/2020
Director/Board Member 68 10/02/2020
Director/Board Member 63 15/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
05/10/26 Sell

Executive/Senior Manager

-4,126 0.0009%
30/09/26 Free

Director

642 0.0001%
28/09/26 Sell

Executive/Senior Manager

-4,126 0.0009%
Change 5-day change 1-year change 3-year change Capi.($)
+0.05%+5.64%+66.26%+127.59% 27.72B
-0.78%+5.31%+59.20%+120.75% 1,144B
-1.07%+0.84%+33.44%+69.13% 625B
-1.94%-0.02%+22.48%+95.82% 511B
+0.54%+5.69%+39.60%+65.02% 377B
+0.47%+0.85%+69.63%+43.81% 366B
+0.30%+3.44%+21.35%+50.15% 291B
-0.03%+2.55%+1.12%+24.89% 262B
-0.27%+2.66%+45.27%+60.21% 237B
-2.15%-0.10%+23.62%+97.77% 194B
Average -0.48%+6.68%+38.20%+75.51% 403.56B
Weighted average by Cap. -0.65%+6.93%+40.69%+81.48%

Financials

2026 *2027 *
Net sales 3.5B 3.12B 2.89B 2.62B 4.93B 331B 4.99B 34.67B 13.6B 174B 13.15B 12.87B 554B 3.82B 3.4B 3.15B 2.85B 5.37B 360B 5.44B 37.78B 14.82B 189B 14.33B 14.03B 604B
Net income 1.47B 1.31B 1.21B 1.09B 2.06B 138B 2.09B 14.49B 5.69B 72.67B 5.5B 5.38B 232B 1.77B 1.58B 1.46B 1.32B 2.49B 167B 2.52B 17.53B 6.88B 87.88B 6.65B 6.51B 280B
Net Debt 8.99B 8.01B 7.42B 6.71B 12.65B 849B 12.8B 88.96B 34.91B 446B 33.74B 33.03B 1,422B 9.1B 8.11B 7.51B 6.79B 12.8B 859B 12.95B 90.01B 35.32B 451B 34.13B 33.42B 1,438B
Projected Income Statement - Annual - Royalty Pharma plc
Logo Royalty Pharma plc
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. It collaborates with innovators from academic institutions, research hospitals and non-profits from small and mid-cap biotechnology companies to global pharmaceutical companies. It funds innovation in the biopharmaceutical industry both directly and indirectly. Directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirectly when it acquires existing royalties from the original innovators. Its portfolio includes royalties on more than 35 commercial products, including Vertex's Trikafta and Alyftrek, GSK's Trelegy, Roche's Evrysdi, Johnson & Johnson's Tremfya, Biogen's Tysabri and Spinraza, Servier's Voranigo, AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Pfizer's Nurtec ODT, and Gilead's Trodelvy, and over 17 development-stage product candidates.
Employees
100
Date Price Change Volume
21/10/26 US$62.33 +0.13% 1,247,894
20/10/26 US$62.25 +3.29% 2,493,205
19/10/26 US$60.27 -1.13% 2,813,226
16/10/26 US$60.96 +2.25% 5,786,552
15/10/26 US$59.62 +1.07% 3,407,113
Trader
Investor
Global
Quality
ESG MSCI
AAA
MarketScreener Ratings - Royalty Pharma plc
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
62.25USD
Average target price
65.38USD
Spread / Average Target
+5.02%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Royalty Pharma plc
  1. Stock Market
  2. Stocks
  3. RPRX Stock